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Macrolide antibiotics, such as Clarithromycin (Cla), have been proven
to exert anti-tumour activity in several preclinicalmodels of different
types of cancer. Cla can exert its anti-tumour effects throughdifferent
mechanisms, e.g. by blocking the autophagic flux, inducing apoptosis
or inhibiting tumour-induced angiogenesis. The clinical benefit of Cla
in treating various tumours in combination with conventional
treatment was confirmed in extensive clinical studies in patients
suffering from non-small cell lung cancer, breast cancer, multiple
myeloma and other haematologicalmalignancies. Data regarding the
anti-cancer effect of Cla on Colorectal Cancer (CRC) are still lacking.
This article shares data on the in vivo efficacy of Cla in two xenograft
models of CRC. Our results show that Cla treatment reduces tumour
growth and increases the overall survival in CRC mouse xenograft
models. Moreover, the Western blot analysis of autophagic and
apoptotic markers suggests that the anti-tumour effects of Cla are
related to a modulation of both cellular processes. The data suggest
that it will worth consider Cla as treatment option for CRC patients.
© 2019 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).ental and Clinical Medicine, Section of Internal Medicine, University of
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Specifications Table
Subject Medicine
Specific subject area Cancer research, Pharmacology and Toxicology
Type of data Graph
Figure
Time course of tumour growth
Overall survival
Western blot
How data were
acquired
Tumour growth was monitored by external measurement using calipers.
WB images were acquired with an Epson 3200 scanner.
Densitometric analysis was performed using ImageJ.
Data format Raw and analysed data
Parameters for data
collection
Subcutaneous experiments: mice were treated with 100 ml of saline (Control) or Cla (15mg kg1) by
oral gavage for 2 weeks daily, starting 1 week after cell inoculum. Experimental groups comprised:
control group, n ¼ 4 mice (n ¼ 8 tumour masses); Cla-administered group, n ¼ 5 mice (n ¼ 10
tumour masses).
Survival experiments: mice were treated as above. Each experimental group comprised n ¼ 10
mice.
Description of data
collection
Tumour growth was monitored by external measurement using calipers. The volume of tumour
masses measured at sacrifice (3 weeks after inoculum) was calculated by applying the ellipsoid
equation, while during the experiment it was estimated with the following equation: 0.5 x Length x
Width2.
Whole protein lysates were obtained from a portion of excised tumour masses at sacrifice. Samples
were homogenized in cold protein extraction buffer and sonicated for 30 min.
Survival was monitored until death.
Data source location Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Data accessibility With the article
Value of the data
 The in vivo effect of Clarithromycin has been previously described for different cancer model, except for Colorectal Cancer.
 This research analysed the in vivo effect of Clarithromycin in two different xenograft models of Colorectal Cancer: with the
subcutaneous model we provide new insights about the effect of the drug on both tumour growth and expression of
autophagic and apoptotic proteins; with the intraperitoneal model we evaluated the overall survival and the toxicity of
the drug.
 Valuable for researchers interested in the impact of Macrolide Antibiotics on Cancer treatment.
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The in vivo efficacy of Cla was evaluated in two preclinical CRC xenograft models, both employing
human CRC cells: HCT116 cells xenografted subcutaneously, and LS174T cells injected intraperitoneally.
In both cases, immunodeficient mice were used. Compared to the control group, the volumes of the
subcutaneous tumours were significantly (P ¼ 0.0001) reduced after 2 weeks of Cla treatment (15
mg Kg1, daily, by oral gavage) (Fig. 1A). The same treatment schedule produced a significant increase
of the overall survival of LS174T-injected mice (Fig. 1B) (P ¼ 0.0355), without inducing toxicity. No
death or significant body weight change was observed in Cla-treatment group (Fig. 1C).
Two weeks after treatment with Cla, mice subcutaneously injected with HCT116 were sacrificed,
and tumourmasses were collected, in order to analyse the effects of the drug on the autophagic process
studying the expression of two autophagic markers: (1) the conversion of the soluble form of the
microtubule-associated protein 1-light chain 3 (LC3-I), to the lipidated autophagosome-associated
form, LC3-II, and (2) the ubiquitin-binding protein p62/sequestome 1 (p62/SQSTM1) [1]. Compared
to control, the LC3-II/LC3-I ratio was significantly increased and the p62/SQSTM1 levels were signifi-
cantly decreased in Cla-treated tumours (Fig. 2A). Then we studied the activation of caspase 3 in
tumour masses, as a marker of apoptosis induction [2]. Significant reduction in protein levels of pro-
caspase 3, correlated to increase in cleaved (activated form) caspase 3, was detected in the tumour
masses of Cla-treated group (Fig. 2A). Finally, phosphorylation of Erk 1/2 and Akt, pathways involved
Fig. 1. Efficacy of Clarithromycin in two xenograft models of Colorectal Cancer. (A) Time course of tumour growth in control and
Cla (15 mg Kg1) treated nude mice, subcutaneously (s.c.) injected with HCT116 cells (3  106/flank). Seven days after the inoculum,
mice were treated with saline (control) and Cla. Cla was daily administered by oral gavage (o.g.) for 14 days, as reported in the
schematic representation of treatment regime. Data presented as mean ± SEM of 8 masses for control group (n ¼ 4 mice) and 10
masses for Cla group (n ¼ 5 mice). **, P ¼ 0.0001 (Student's t-test). (B) Nude athimic mice were injected with LS174T cells
(10  106 cells i.p.) and starting from day 7, animals were treated daily with saline (control, n¼ 10) and Cla (15 mg kg1, by o.g., n¼ 10),
as reported in the schematic representation of treatment regime. Survival curves of each experimental group, estimated by Kaplan and
Meier analysis are reported. *, P ¼ 0.0355 (Gehan-Breslow-Wilcoxon Test). (C) Body weight of LS174T xenograft-bearing nude mice,
treated as in (B). Data presented as mean ± SEM (n ¼ 10 mice for each treatment group). ns ¼ not significant (Student's t-test).
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by Cla treatment (Fig. 2B).
2. Experimental design, materials, and methods
2.1. In vivo tumour xenograft models
Mice experiments were performed at the Laboratory of Genetic Engineering for the Production of
AnimalModels (LIGeMA) at the Animal House of the University of Florence (Ce.S.A.L.). Micewere housed
in filter-top cages with a 12-h dark-light cycle, and had unlimited access to food and water. Procedures
were conducted according to the laws for experiments on live animals (Directive 2010/63/EU), and
approved by the Italian Ministry of Health (authorization n 114/2016-PR and n 1279/2015-PR).
For subcutaneous xenografts, female nude mice (Envigo Laboratories) aged five to six weeks were
injected subcutaneously in either flanks with 3  106 HCT116 cells, resuspended in 100 ml complete
medium. After cell inoculation, mice were monitored daily to ensure they did not show any signs of
suffering or disease (such as weight loss, abdominal distension, impaired movement, edema in the
injection area). Mice were treated with 100 ml of saline or Cla (15 mg kg1) by oral gavage (o.g.) for two
weeks daily, starting one week after inoculation. Experimental groups comprised: control group, n ¼ 4
mice (n ¼ 8 tumour masses); Cla-administered group, n ¼ 5 mice (n ¼ 10 tumour masses). Tumour
growth was monitored by external measurement using calipers. The volume of tumour masses
measured at sacrifice (3 weeks after inoculum)was calculated by applying the ellipsoid equation, while
during the experiment it was estimated with the following equation: 0.5 x Length x Width2.
For survival experiments, female nude mice aged five to six weeks were injected intraperitoneally
(i.p.) with 107 LS174T cells, resuspended in 100 ml EMEM plus 20% Matrigel (20 mg/ml). Mice were
treated with 100 ml of saline or Cla (15 mg kg1) by o.g. daily, starting one week after inoculation, and
survival was monitored until death. Each experimental group comprised n ¼ 10 mice.
2.2. Western blot (WB) analysis
For tumour lysates, whole protein lysates were obtained from a portion of excised tumour masses
frommice injected with HCT116 cells. Samples were homogenized in cold protein extraction buffer (1X
Cell Lysis Buffer; Cell Signaling Technology, #9803) and sonicated for 30 min.
Fig. 2. Clarithromycin-induced modulation of markers of autophagy and apoptosis in tumour masses. (A-B) WB analysis of the
protein levels of phospho-ERK1/2Thr202/Tyr204, phospho-AktThr308, pro-caspase 3, cleaved caspase 3, LC3 and p62/SQSTM1 in the total
lysates of HCT116 tumour xenografts of mice treated as in (Fig. 1A). The membranes were reprobed with anti-ERK1/2, anti-Akt or
anti-tubulin antibodies. The corresponding densitometric results are given in the bar graphs; data shown as mean ± SEM (n ¼ 4
different tumour masses for each treatment group). *, P < 0.05 (Student's t-test).
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pAb against LC3A/B (#4108; dilution 1:1000), the rabbit mAb against SQSTM1/p62 (clone D5E2, #8025;
dilution 1:1000), the rabbit mAb against Caspase 3 (clone 8G10, #9665; dilution 1:1000), and the rabbit
pAb against phospho-44/42 MAPK (Erk1/2) (Thr202/Tyr204, #9101; dilution 1:1000) were purchased
from Cell Signaling Technology. The mouse mAb against phospho-AKT1/2/3 (clone B-5, sc-271966;
dilution 1:500), the rabbit pAb against AKT1/2/3 (clone H-136, sc8312; dilution 1:500), and the rab-
bit pAb against ERK1/2 (clone H-72, sc-292838; dilution 1:200) were purchased from Santa Cruz
Biotechnology. The anti-a-tubulin mouse mAb (T9026; dilution 1:500) was used as loading control.
Anti-rabbit IgG peroxidase-conjugated (A0545; dilution 1:10000) and anti-mouse IgG peroxidase
antibodies (A4416; dilution 1:5000) were used as secondary antibodies.
WB images were acquired with an Epson 3200 scanner. Densitometric analysis was performed
using ImageJ on two different scans, after background subtraction, from at least three different ex-
periments, as previously described [8].
2.3. Statistical analysis
Data are given as mean values ± standard error of the mean (SEM). The number of independent
experiments is indicated in the Figure legends as n. Statistical comparisons were performed with
GraphPad Prism 6.0e (GraphPad Software, San Diego, USA). Unless otherwise indicated, for compari-
sons between Cla-treated and Control group, we used Student's t-test and P values are reported as *,
P < 0.05.
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